Acadian Asset Management’s Krystal Biotech KRYS Stock Holding History

Acadian Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81K	Buy	+218	New	+$65.1K	﹤0.01%	1793
2024 Q4	–	Sell	-2,280	Closed	-$415K	–	1914
2024 Q3	$415K	Buy	+2,280	New	+$440K	﹤0.01%	1129
2020 Q1	–	Sell	-5,032	Closed	-$279K	–	1859
2019 Q4	$279K	Sell	5,032 -7,921	-61%	-$389K	﹤0.01%	1212
2019 Q3	$450K	Sell	12,953 -19,737	-60%	-$882K	﹤0.01%	1112
2019 Q2	$1.32M	Buy	32,690 +12,953	+66%	+$423K	0.01%	733
2019 Q1	$649K	Sell	19,737 -821	-4%	-$19.4K	﹤0.01%	1032
2018 Q4	$427K	Hold	20,558	–	–	﹤0.01%	944
2018 Q3	$361K	Buy	20,558 +8,356	+68%	+$140K	﹤0.01%	956
2018 Q2	$182K	Buy	12,202 +10,331	+552%	+$116K	﹤0.01%	1107
2018 Q1	$19K	Buy	+1,871	New	+$18.4K	﹤0.01%	1498

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management's KRYS Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 218 shares worth $81K. The stake represents ﹤0.01% of the portfolio and ranks #1793 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in KRYS as recently as Q3 2024.

Acadian Asset Management first reported a position in KRYS in Q1 2018 and has held it in 10 quarters since. The position peaked at $1.32M in Q2 2019. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Acadian Asset Management held 218 shares of Krystal Biotech worth $81K as of Q2 2026.
Krystal Biotech was a new Acadian Asset Management position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1793 holding.
Acadian Asset Management first reported a position in Krystal Biotech in Q1 2018 and has held it in 10 quarters since.
Acadian Asset Management's Krystal Biotech position peaked at $1.32M in Q2 2019.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.